Eli Lilly and Company (NYSE: LLY) announced it will begin enrolling patients this month in two separate but identical Phase III clinical trials of solanezumab(i), previously referred to as LY2062430, an anti-amyloid beta monoclonal antibody being investigated as a potential treatment to delay the progression of mild to moderate Alzheimer"s disease. The trials, called EXPEDITION and EXPEDITION 2, will each include a treatment period that lasts 18 months and are expected to enroll a total of 2,000 patients age 55 and over from 16 countries.
Dr. Jonathan C. Song, director of the Cornea Institute in the Vision Center at Childrens Hospital Los Angeles and an eye surgeon specializing in corneal diseases and transplantation, has just returned from a medical mission in which he worked with Syrian and Iraqi eye surgeons at the Syrian city of Dier Ezzor. During the medical mission, May 18-22, Dr. Song saw 50 patients and performed eight corneal transplants and five cataract surgeries. In addition to holding training sessions with Syrian ophthalmologists, he also lectured to 25 Syrian and Iraqi medical professionals about advanced eye surgery techniques.